Neuronetics (STIM)
(Delayed Data from NSDQ)
$1.80 USD
+0.02 (1.12%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $1.79 -0.01 (-0.56%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.80 USD
+0.02 (1.12%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $1.79 -0.01 (-0.56%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Zacks News
Anthem (ANTM) Rises 3.7% Since Q4 Earnings, Reiterates View
by Zacks Equity Research
Anthem's (ANTM) Medicaid footprint is likely to grow on the back of the pending acquisition of Paramount Advantage's Ohio contracts, as service is expected to commence in July.
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 12.12% and 2.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -266.67% and 19.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
After Plunging 24.2% in 4 Weeks, Here's Why the Trend Might Reverse for Neuronetics (STIM)
by Zacks Equity Research
Neuronetics (STIM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Analysts Estimate Neuronetics (STIM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 31st
by Zacks Equity Research
AMWD, CYTK, STIM, OLLI, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on August 31, 2021.
New Strong Sell Stocks for August 25th
by Zacks Equity Research
BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021
New Strong Sell Stocks for August 6th
by Zacks Equity Research
AVA, IDN, KOPN, PRIM, and STIM have been added to the Zacks Rank #5 (Strong Sell) List on August 6, 2021.
Neuronetics (STIM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of -20.83% and -3.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neuronetics (STIM) Soars 39.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Neuronetics (STIM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 6.06% and 6.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 24.00% and 2.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Soars 6.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Neuronetics (STIM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neuronetics (STIM) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Neuronetics (STIM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 41.94% and 11.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 19.61% and 16.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Neuronetics (STIM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neuronetics (STIM) Looks Good: Stock Adds 11.3% in Session
by Zacks Equity Research
Neuronetics (STIM) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
Neuronetics (STIM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of -54.55% and -3.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Snap Up These 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top--ranked stocks with rising P/E to realize outsized gains.
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 8.89% and 2.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Neuronetics (STIM) Q4 Earnings Expected to Decline
by Zacks Equity Research
Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 9.76% and -0.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?